Ono Pharmaceutical Co Ltd
TSE:4528
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 745
2 849
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Ono Pharmaceutical Co Ltd
Ono Pharmaceutical Co Ltd
Income to Minority Interest
Ono Pharmaceutical Co Ltd
Income to Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income to Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ono Pharmaceutical Co Ltd
TSE:4528
|
Income to Minority Interest
-¥39m
|
CAGR 3-Years
20%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income to Minority Interest
-¥173m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
24%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income to Minority Interest
-¥3.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Income to Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ono Pharmaceutical Co Ltd
Glance View
Ono Pharmaceutical Co., Ltd., a leader in the Japanese biopharmaceutical landscape, has carved out a reputation for innovation and dedication to addressing unmet medical needs. Founded in 1717, this company has evolved over the centuries and transformed from a traditional medicine supplier into a cutting-edge player in the global pharmaceutical arena. Ono’s commitment to research and development is highlighted by its focus on oncology, immunology, and neurology, boasting a robust pipeline that includes groundbreaking therapies, such as the highly regarded monoclonal antibody, Opdivo (nivolumab). Opdivo has not only become a cornerstone in cancer treatment but also solidified Ono’s position as the go-to partner for health institutions looking to leverage advanced therapeutics for patient care. For investors, Ono Pharmaceutical represents a compelling opportunity within the biopharmaceutical sector, given its strong intellectual property portfolio and solid financial performance. The company has cultivated strategic collaborations with prominent global players, expanding its reach beyond Japan and accessing international markets. With revenue driven by both its proprietary drugs and partnerships, Ono demonstrates resilience amid fluctuating industry conditions. Moreover, the firm's ongoing investments in innovative development programs signal a forward-thinking approach, likely to yield new products that can drive future growth. As global healthcare increasingly leans towards personalized medicine and novel treatments, Ono Pharmaceutical stands poised to capitalize on these trends, making it a noteworthy consideration for investors seeking long-term value and impact in the healthcare space.
See Also
What is Ono Pharmaceutical Co Ltd's Income to Minority Interest?
Income to Minority Interest
-39m
JPY
Based on the financial report for Sep 30, 2024, Ono Pharmaceutical Co Ltd's Income to Minority Interest amounts to -39m JPY.
What is Ono Pharmaceutical Co Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 10Y
15%
Over the last year, the Income to Minority Interest growth was 66%. The average annual Income to Minority Interest growth rates for Ono Pharmaceutical Co Ltd have been 20% over the past three years , 28% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
